Dagrocorat
Dagrocorat is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treatment of rheumatoid arthritis but was never marketed.
Developmental code name[edit | edit source]
The delopmental code names were: PF-00251802, PF-251802
Never marketed[edit | edit source]
The medication was never marketed by the pharmaceutical company for unknown reasons.
Mechanism of action[edit | edit source]
Dagrocorat is a novel and dissociated glucocorticoid receptor agonist.
Originator[edit | edit source]
Pfizer
Class of drug[edit | edit source]
Anti-inflammatories; Antirheumatics; Phenanthrenes; Pyridines; Small molecules
Orphan Drug Status[edit | edit source]
No
New Molecular Entity[edit | edit source]
Yes
Highest Development Phases[edit | edit source]
Phase 1
Current status[edit | edit source]
Discontinued
Proposed indication[edit | edit source]
Rheumatoid arthritis
Most Recent Events[edit | edit source]
- 27 Jan 2010Discontinued - Phase-I for Rheumatoid arthritis in USA (unspecified route)
- 03 Oct 2008Phase-I trials in Rheumatoid arthritis in USA (unspecified route)
Related molecules[edit | edit source]
Dagrocorat-2
 | This hormonal preparation article is a stub. You can help WikiMD by expanding it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD
